Compare IBG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBG | JAGX |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.4M |
| IPO Year | 2022 | 2014 |
| Metric | IBG | JAGX |
|---|---|---|
| Price | $0.83 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.8K | ★ 1.3M |
| Earning Date | 05-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | N/A | $77.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.65 | $0.20 |
| 52 Week High | $6.28 | $41.53 |
| Indicator | IBG | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 39.82 |
| Support Level | $0.76 | $0.39 |
| Resistance Level | $0.96 | $0.79 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | -0.00 | -0.28 |
| Stochastic Oscillator | 22.62 | 0.72 |
Innovation Beverage Group Ltd is a developer, manufacturer and exporter of a growing portfolio of 75 formulations across 14 alcoholic and non-alcoholic brands of beverages such as Australian Bitters company. It has two reportable segments: Australia and the United States. The Australia segment mainly consists of its Australian beverage operations and corporate activities, while the United States segment consists of the operations of its United States subsidiaries. Majority of revenue comes from Australia. Its brands are Australian Bitters Company, Bittertales Aromatic, Twisted Shaker Cocktails, Drummerboy Non Alcoholic Spirits, and Wired For Wine.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.